

# ISO 5840-2:2021 (E)

## Cardiovascular implants — Cardiac valve prostheses — Part 2: Surgically implanted heart valve substitutes

---

### Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms and definitions
4	Abbreviations
5	Fundamental requirements
6	Device description
6.1	General
6.2	Intended use
6.3	Design inputs
6.3.1	Operational specifications
6.3.2	Performance specifications
6.3.2.1	General
6.3.2.2	Surgical heart valve substitute minimum performance requirements
6.3.2.3	Accessories
6.3.2.4	Implant procedure
6.3.3	Packaging, labelling, and sterilization
6.4	Design outputs
6.5	Design transfer (manufacturing verification/validation)
6.6	Risk management
7	Design verification and validation
7.1	General requirements
7.2	In vitro assessment
7.2.1	General
7.2.2	Test conditions, sample selection, and reporting requirements
7.2.3	Material property assessment
7.2.4	Hydrodynamic performance assessment
7.2.5	Structural performance assessment
7.2.5.1	General
7.2.5.2	Implant durability assessment
7.2.5.3	Device structural component fatigue assessment
7.2.5.4	Component corrosion assessment
7.2.5.5	Cavitation (rigid valves)
7.2.6	Design- or procedure-specific testing
7.2.6.1	General
7.2.6.2	Visibility
7.2.7	Device MRI compatibility
7.2.8	Simulated use
7.2.9	Human factors/usability assessment
7.2.10	Implant thrombogenic and haemolytic potential assessment
7.3	Preclinical in vivo evaluation
7.3.1	General
7.3.2	Overall requirements
7.3.3	Methods

- 7.3.4 Test report
- 7.4 Clinical investigations
  - 7.4.1 General
  - 7.4.2 Study considerations
  - 7.4.3 Study endpoints
  - 7.4.4 Ethical considerations
  - 7.4.5 Pivotal studies: Distribution of subjects and investigators
  - 7.4.6 Statistical considerations including sample size and duration
    - 7.4.6.1 General
    - 7.4.6.2 Objective performance criteria for established device designs
    - 7.4.6.3 Study designs for novel devices
  - 7.4.7 Patient selection criteria
  - 7.4.8 Valve thrombosis prevention
  - 7.4.9 Clinical data requirements
    - 7.4.9.1 General
    - 7.4.9.2 Baseline data
    - 7.4.9.3 Peri-procedure data
    - 7.4.9.4 Follow-up data
    - 7.4.9.5 Clinical investigation analysis and reporting
    - 7.4.9.6 Post-market clinical follow-up

**Annex A (informative) Surgical heart valve substitute hazard analysis example**

- A.1 Hazards, foreseeable sequence of events, hazardous situations, and associated harms

**Annex B (informative) In vitro procedures for testing unstented or similar valves in compliant chambers**

- B.1 General
- B.2 Compliant chamber specifications
- B.3 Test procedures using compliant chambers
  - B.3.1 Pulsatile-flow pressure difference
  - B.3.2 Pulsatile-flow regurgitation
  - B.3.3 Reference valves for hydrodynamic testing
  - B.3.4 Wear/durability

**Annex C (informative) Preclinical in vivo evaluation**

- C.1 General
- C.2 Disposition of evaluations
  - C.2.1 General
  - C.2.2 Haemodynamic performance
  - C.2.3 Usability
  - C.2.4 Acoustic characteristics
  - C.2.5 Interference with adjacent anatomical structures
  - C.2.6 Haemolysis
  - C.2.7 Thrombo-embolic events
  - C.2.8 Calcification/mineralization
  - C.2.9 Pannus formation/tissue ingrowth
  - C.2.10 Structural valve deterioration and non-structural dysfunction
  - C.2.11 Assessment of valve and non-valve related pathology
  - C.2.12 Cavitation

**Annex D (informative) Description of the surgical heart valve substitute and system**

- D.1 General
- D.2 Chemical treatments, surface modifications, or coatings
- D.3 Component description
  - D.3.1 General
  - D.3.2 Examples of components of some surgical heart valve substitutes
- D.4 Accessories

**Annex E (informative) Examples of components of some surgical heart valve substitutes and systems**

**Annex F (informative) Guidelines for verification of hydrodynamic performance — Pulsatile flow testing**

- F.1 General
- F.2 Pulsatile-flow testing

- F.2.1 Measuring equipment accuracy
- F.2.2 Test apparatus requirements
- F.2.3 Test procedure
- F.2.4 Test report

**Annex G (informative) Examples of design specific testing**

- G.1 Sewing ring integrity
- G.2 Stent creep
- G.3 Environmental degradation
- G.4 Static pressure; “burst” test
- G.5 Calcification (flexible valve)
- G.6 Particulate generation
- G.7 Effects of device post-dilatation
- G.8 Leaflet impingement force (rigid valves)
- G.9 Leaflet escape force (rigid valves)
- G.10 Sewing ring push-off
- G.11 Sewing ring torque (rigid valves)
- G.12 Device migration resistance

**Annex H (informative) Fatigue assessment**

- H.1 General
- H.2 Fatigue crack growth, da/dN, characterization
- H.3 Damage tolerance analysis

**Annex I (normative) Methods of evaluating clinical data against objective performance criteria**

- I.1 General
- I.2 Objective performance criteria methodology

**Annex J (normative) Adverse event classification during clinical investigation**

- J.1 General
- J.2 Evaluation
- J.3 Data collection requirements
- J.4 Adverse events
- J.5 Adverse device effects
- J.6 Device deficiencies
- J.7 Classification of causal relationships
- J.8 Classification of adverse events
- J.8.1 General
- J.8.2 Examples of adverse events
- J.9 Follow up of SAEs
- J.10 Device-related mortality

Page count: 51